Mark A. Helvie

Mark A. Helvie

Auto-generated profile, based on publicly available information

Mark A. Helvie

Univ. of Michigan Health System (United States)

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Radiologic Clinics of North America
Verified
Journal Article
Closed access
MHMark A. Helvie
Mark A. Helvie

1 September 2006 in Radiology
Verified
Journal Article
Closed access
KMKatherine E. Martin
Katherine E. Martin
MHMark A. Helvie
Mark A. Helvie
CZChuan Zhou
Chuan Zhou
MRMarilyn A. Roubidoux
Marilyn A. Roubidoux
JBJanet E. Bailey
Janet E. Bailey
HCHeang-Ping Chan
Heang-Ping Chan

19 May 2014 in Cancer
Verified
Journal Article
Open access
PDF file
MHMark A. Helvie
Mark A. Helvie
JCJoanne T. Chang
Joanne T. Chang
RHR. Edward Hendrick
R. Edward Hendrick
MBMousumi Banerjee
Mousumi Banerjee
BACKGROUND: Mammographic screening is expected to decrease the incidence of late‐stage breast cancer. In the current study, the authors determined the decrease in late‐stage cancer incidence and the changes in invasive cancer incidence that occurred in the mammographic era after adjusting for prescreening temporal trends.METHODS: Breast cancer incidence and stage data were obtained from the Surveillance, Epidemiology, and End Results program. The premammography period (1977‐1979) was compared with the mammographic screening period (2007‐2009) for women aged ≥ 40 years. The authors estimated prescreening temporal trends using 5 measures of annual percentage change (APC). Stage‐specific incidence values from 1977 through 1979 (baseline) were adjusted using APC values of 0.5%, 1.0%, 1.3%, and 2.0% and then compared with observed stage‐specific incidence in 2007 through 2009.RESULTS: Prescreening APC temporal trend estimates ranged from 0.8% to 2.3%. The joinpoint estimate of 1.3% for women aged ≥ 40 years approximated the 4‐decade long APC trend of 1.2% noted in the Connecticut Tumor Registry. At an APC of 1.3%, late‐stage breast cancer incidence decreased by 37% (56 cases per 100,000 women) with a reciprocal increase in early‐stage rates noted from 1977 through 1979 to 2007 through 2009. Resulting late‐stage cancer incidence decreased from 21% at an APC of 0.5% to 48% at an APC of 2.0%. Total invasive breast cancer incidence decreased by 9% (27 cases per 100,000 women) at an APC of 1.3%.CONCLUSIONS: There is evidence that a substantial reduction in late‐stage breast cancer has occurred in the mammography era when appropriate adjustments are made for prescreening temporal trends. At background APC estimates of ≥ 1%, the total invasive breast cancer incidence also decreased. Cancer 2014;120:2649–2656. © 2014 American Cancer Society.

1 July 2002 in Radiology
Verified
Journal Article
Closed access
NPNicholas Petrick
Nicholas Petrick
BSBerkman Sahiner
Berkman Sahiner
HCHeang-Ping Chan
Heang-Ping Chan
MHMark A. Helvie
Mark A. Helvie
SPSophie Paquerault
Sophie Paquerault
Lubomir HadjiyskiLubomir Hadjiyski
Lubomir Hadjiyski
To evaluate the performance of a computer-aided diagnosis (CAD) mass-detection algorithm in marking preoperative masses. Digitized mammograms were processed with an adaptive enhancement filter followed by a local border refinement stage. Features were then extracted from each detected structure and used to identify potential masses. The performance of the algorithm was evaluated in independent cases obtained from 263 patients from two institutions. Each case contained one or more pathologically proved breast masses. Contralateral mammograms obtained in the same patients that did not contain a visible lesion were used to estimate the CAD marker rate for the algorithm. The tradeoff between detection sensitivity and the number of CAD marks was analyzed in this study. Malignant masses were detected with the computer in 87% (135 of 156), 83% (130 of 156), and 77% (120 of 156) of the malignant cases at CAD marker rates of 1.5, 1.0, and 0.5 marks per mammogram, respectively. The difference between malignant mass-detection performance in subsets of cases collected at each institution was found to be less than 1%. The detection accuracy for benign masses was lower than that for malignant masses. This mass-detection algorithm had a high sensitivity for detection of malignant masses. It may be useful as a second opinion in mammographic interpretation.


1 September 2007 in Radiologic Clinics of North America
Verified
Journal Article
Closed access
MHMark Helvie
Mark Helvie